Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women.

Vogel VG.

Breast Cancer (Dove Med Press). 2011 Oct 20;3:127-37. doi: 10.2147/BCTT.S11288. Review.

2.

Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.

Vogel VG.

Curr Drug Targets. 2011 Dec;12(13):1874-87. Review.

PMID:
21158712
3.

American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM; American Society of Clinical Oncology..

J Clin Oncol. 2009 Jul 1;27(19):3235-58. doi: 10.1200/JCO.2008.20.5179.

4.

Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.

Ganz PA, Land SR.

Menopause. 2008 Jul-Aug;15(4 Suppl):797-803. doi: 10.1097/gme.0b013e31817be9af. Review.

PMID:
18596601
5.

Chemoprevention for high-risk women: tamoxifen and beyond.

Fabian CJ, Kimler BF.

Breast J. 2001 Sep-Oct;7(5):311-20. Review.

PMID:
11906441
6.

Selective estrogen-receptor modulators.

Cosman F.

Clin Geriatr Med. 2003 May;19(2):371-9. Review.

PMID:
12916292
7.

The selective estrogen receptor modulators in breast cancer prevention.

Li F, Dou J, Wei L, Li S, Liu J.

Cancer Chemother Pharmacol. 2016 May;77(5):895-903. doi: 10.1007/s00280-016-2959-0. Review.

PMID:
26787504
8.

Chemoprevention of breast cancer: implications for postmenopausal women.

Fabian CJ, Kimler BF.

Drugs Aging. 2002;19(1):43-78. Review.

PMID:
11929326
9.

SERMs for the treatment and prevention of breast cancer.

Swaby RF, Sharma CG, Jordan VC.

Rev Endocr Metab Disord. 2007 Sep;8(3):229-39. Review.

PMID:
17440819
10.

Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.

Vogel VG, Costantino JP, Wickerham DL, McCaskill-Stevens W, Clarfeld RB, Grant MD, Wolmark N.

J Natl Cancer Inst Monogr. 2010;2010(41):181-6. doi: 10.1093/jncimonographs/lgq041. Review.

11.

Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, Pajon ER, Wade JL 3rd, Dakhil S, Lockhart JB Jr, Wolmark N, Ganz PA.

JAMA. 2006 Jun 21;295(23):2742-51. Erratum in: JAMA. 2007 Sep 5;298(9):973.

PMID:
16754728
12.

Chemoprevention in postmenopausal women.

Rastogi P.

Menopause. 2008 Jul-Aug;15(4 Suppl):810-5. doi: 10.1097/gme.0b013e318178863e. Review.

PMID:
18596603
13.

Raloxifene: a review of its use in the prevention of invasive breast cancer.

Moen MD, Keating GM.

Drugs. 2008;68(14):2059-83. Review.

PMID:
18778124
14.

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP)..

JAMA. 2006 Jun 21;295(23):2727-41. Erratum in: JAMA. 2006 Dec 27;296(24):2926. JAMA. 2007 Sep 5;298(9):973.

PMID:
16754727
15.

Breast cancer prevention with selective estrogen receptor modulators: a perspective.

Pritchard KI.

Ann N Y Acad Sci. 2001 Dec;949:89-98. Review.

PMID:
11795385
16.

Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.

Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN.

Ann Intern Med. 2002 Jul 2;137(1):59-69. Review.

PMID:
12093250
17.

From adjuvant therapy to breast cancer prevention: BCPT and STAR.

Dunn BK, Ford LG.

Breast J. 2001 May-Jun;7(3):144-57. Review.

PMID:
11469927
18.
19.

Selective estrogen modulators in menopause.

Gambacciani M.

Minerva Ginecol. 2013 Dec;65(6):621-30.

PMID:
24346250
20.

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project..

Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076.

Supplemental Content

Support Center